CKD in patients without diabetes

CFG – 1

Intended venue: ASN 2026

Intended Audience: Nephrologist (including APP), Internal Medicine (including APP), PCPs (including APP), 
Cardiologist (including APP)

Bayer TA Rationale for Educational Support:

• Educate clinicians on the unmet needs of patients with CKD without diabetes, reinforcing the residual cardio-renal risk in patients with non-diabetic CKD
• Improve awareness of the cardiovascular risk associated with CKD without diabetes
• Promote understanding of guideline-recommended screening with urine albumin-creatinine ratio (uACR) and estimated glomerular filtration rate (eGFR) for diagnosis and monitoring of CKD
• Educate on recent advances for patients with CKD without diabetes

Preferred Format:

• Podcast and/or innovative format
• Enduring
• Downloadable slides
• Incorporation of social media outreach (You-Tube, FaceBook, Spotify, LinkedIn, Twitter)
• Live Virtual

Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME). The proposal should include:

• Needs assessment
• Educational design and rationale for selection (where applicable)
• Learning Objectives & Draft Agenda
• Proposed Faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan
• Detailed budget (please use the template available on the website)

Provider Justification:

Copy of most recent accreditation letter and status

Process:

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References

1. Stevens P, Ahmed S, Carrero J et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 105, S117-S314
2. Hiddo J L Heerspink, Rajiv Agarwal, George L Bakris, David Z I Cherney, Carolyn S P Lam, Brendon L Neuen, Pantelis A Sarafidis, Katherine R Tuttle, Christoph Wanner, Meike D Brinker, Sara Dizayee, Peter Kolkhof, Patrick Schloemer, Paula Vesterinen, Vlado Perkovic, for the FIND-CKD investigators , Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial, Nephrology Dialysis Transplantation, Volume 40, Issue 2, February 2025, Pages 308–319.
3. Hiddo J.L. Heerspink, Ph.D., Bergur V. Stefánsson, M.D., Ricardo Correa-Rotter, M.D., Glenn M. Chertow, M.D., Tom Greene, Ph.D., Fan-Fan Hou, M.D., Johannes F.E. Mann, M.D. , for the DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446.
4. The EMPA-KIDNEY Collaborative Group*Author Info & Affiliations. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023;388:117-127